The choice of dual targeting (EGFR + IL13Rα2) was deliberate: both antigens are frequently co-expressed in glioblastoma, reducing the likelihood of antigen escape—a common failure mode in single-target CAR-T therapies. This evidence concerns the gene IL13RA2 and glioblastoma.